-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly Q3 net income rises 16% to $6.45 billion; Q3 revenue climbs 39% to $24.4 billion

PUBT·10/29/2026 10:54:09
Eli Lilly Q3 net income rises 16% to $6.45 billion; Q3 revenue climbs 39% to $24.4 billion
  • Eli Lilly’s third-quarter 2026 reported earnings rose 16% year over year to $7.22 per share.
  • Revenue climbed 39% to $24.4 billion, driven primarily by Mounjaro and Zepbound.
  • Mounjaro revenue jumped 65% to $10.72 billion, while Zepbound revenue increased 49% to $5.35 billion.
  • Mounjaro secured FDA approval to reduce cardiovascular risk in adults with type 2 diabetes.
  • Full-year 2026 revenue guidance rose to $91 billion–$92 billion from $85 billion–$87 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE84126) on October 29, 2026, and is solely responsible for the information contained therein.